Literature DB >> 20874087

West Nile fever characteristics among viremic persons identified through blood donor screening.

Shimian Zou1, Gregory A Foster, Roger Y Dodd, Lyle R Petersen, Susan L Stramer.   

Abstract

Nucleic acid testing (NAT) of blood donors provides opportunities for identifying West Nile virus (WNV)-infected persons before symptoms develop and for characterizing subsequent illness. From June 2003 through 2008, the American Red Cross performed follow‐up interviews with and additional laboratory testing for 1436 donors whose donations had initial test results that were reactive for WNV RNA; 821 of the donors were subsequently confirmed to have WNV infection, and the remainder were unconfirmed or determined to have false‐positive results. Symptoms attributed to WNV infection were determined by comparing symptom frequency among 576 donors identified with early WNV infection (immunoglobulin M antibody negative) and those with unconfirmed infection. We estimate that 26% of WNV‐infected persons become symptomatic, defined by the presence of at least 3 of 8 indicator symptoms. Nearly one‐half of symptomatic persons sought medical care; only 5% received a diagnosis of WNV infection. Female subjects and persons with higher viral loads detected in the index donation were more likely than other subjects to develop symptoms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20874087     DOI: 10.1086/656602

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  52 in total

Review 1.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

2.  West nile virus.

Authors:  Georg Pauli; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-07-04       Impact factor: 3.747

3.  MicroRNA reduction of neuronal West Nile virus replication attenuates and affords a protective immune response in mice.

Authors:  Terza Brostoff; Patricia A Pesavento; Christopher M Barker; Joan L Kenney; Elizabeth A Dietrich; Nisha K Duggal; Angela M Bosco-Lauth; Aaron C Brault
Journal:  Vaccine       Date:  2016-09-13       Impact factor: 3.641

4.  Emerging and reemerging neurologic infections.

Authors:  Felicia C Chow; Carol A Glaser
Journal:  Neurohospitalist       Date:  2014-10

Review 5.  Risk factors for West Nile virus infection and disease in populations and individuals.

Authors:  Ruth R Montgomery; Kristy O Murray
Journal:  Expert Rev Anti Infect Ther       Date:  2015-01-30       Impact factor: 5.091

Review 6.  Regulation of cell survival and death during Flavivirus infections.

Authors:  Sounak Ghosh Roy; Beata Sadigh; Emmanuel Datan; Richard A Lockshin; Zahra Zakeri
Journal:  World J Biol Chem       Date:  2014-05-26

Review 7.  Innate Antiviral Immunity in the Skin.

Authors:  Chelsea Handfield; Jeffery Kwock; Amanda S MacLeod
Journal:  Trends Immunol       Date:  2018-03-08       Impact factor: 16.687

Review 8.  West Nile Virus: biology, transmission, and human infection.

Authors:  Tonya M Colpitts; Michael J Conway; Ruth R Montgomery; Erol Fikrig
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 9.  West Nile virus: review of the literature.

Authors:  Lyle R Petersen; Aaron C Brault; Roger S Nasci
Journal:  JAMA       Date:  2013-07-17       Impact factor: 56.272

10.  West Nile Virus Infection in Human and Mouse Cornea Tissue.

Authors:  Bradley J Blitvich; Tian Wang; Vandana Saxena; Shemin Zeng; Karen M Harmon; Matthew D Raymond; Kenneth M Goins; Cynthia R Reed; Robert F Mullins; Mark A Greiner
Journal:  Am J Trop Med Hyg       Date:  2016-09-26       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.